We use cookies to ensure that we give you the best experience on our website Learn more

Home

Saved research

Aug 9, 2019

EFIC Congress 2019 - Pain in Europe XI

GLOSSOPHARYNGEAL NERVE NEURALGIA TREATED WITH TRANSMUCOSAL TOPICAL 2% LIDOCAINE IN ADHESIVE ORAL EXCIPIENT: A CASE REPORT

;

Atypical facial Neuralgia

Neuropathic pain

topical treatment

lidocaine

Abstract

24

Views

24

Views

Abstract

Fullscreen

thumbnail

Keywords

Atypical facial Neuralgia

Neuropathic pain

topical treatment

lidocaine

Abstract

- Background and aims: To explore new treatment for atypical orofacial pain when other treatments have failed. - Methods: 44yo female referred for treatment for glossopharyngeal neuralgia. Before referal the following treatment had already failed: Gabapentinoids, duloxetine, tapenadol, buprenorphine, estelate ganglon blocks, iv lidocaine&ketamine, carbamazepine, biofeedback, cognitive-behavioral therapy and hypnosis. A glossopharyngeal ganglion block was perfomed under CT scan with positive results for a few days. But patient denied new interventional techniques due to her bad experience. Topical intranasal lidocaine for treating the glossopharyngeal ganglion was accepted by the patient as palliative out-of-order treatment. First of all, a cold 2% viscous lidocaine was introduced through the right nose hole with a 20G cannula. Up to 3-4cc could be administered before she reported swallowing. Then a thicker excipient was changedby the pharmacy department to 2% lidocaine in adhesive oral excipient (AOE) leading to adensity similar to pharyngeal mucus. - Results: are shown on table 1. - Conclusions: Transnasal transmucosal topical 2% lidocaine in AOE may be an alternative for the treatment of atypical facial neuralgia. Different concentrations must be explored for greater effectiveness and safety.

Company

Legal

Follow us

© Copyright 2019 Morressier GmbH. All rights reserved.

© Copyright 2019 Morressier GmbH.
All rights reserved.